Sanpras Healthcare Private Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Sanpras Healthcare Private Limited Pharmaceutical Export Portfolio Dataset — 4 Products, $2.3M FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Sanpras Healthcare Private Limited — Pharmaceutical Exporter Profile (2026) | 4 Products, $2.3M Trade | TransData Nexus

Sanpras Healthcare Private Limited

Indian Pharmaceutical Exporter · Gastrointestinal Specialist · $2.3M Total Trade · DGFT Verified

Sanpras Healthcare Private Limited is an Indian pharmaceutical exporter with a total trade value of $2.3M across 4 products in 3 therapeutic categories. Based on 125 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Lactulose ($1.2M), Ambroxol ($551.0K), Bromhexine ($359.7K).

Sanpras Healthcare Private Limited — Export Portfolio & Destination Treemap

Sanpras Healthcare Private Limited pharmaceutical export portfolio — 4 products across 3 therapeutic categories. Source: Indian Customs (DGFT).

Who is Sanpras Healthcare Private Limited? — Company Overview & Market Position

Sanpras Healthcare Private Limited, established on November 9, 2009, is a privately held pharmaceutical company headquartered in Sinnar, Maharashtra, India. The company specializes in the formulation and development of finished pharmaceutical products, focusing on oral liquid formulations such as syrups, suspensions, and solutions. Its Corporate Identification Number (CIN) is U85100MH2009PTC196966, and it is registered under the Registrar of Companies, Mumbai.

The authorized capital of Sanpras Healthcare is ₹3.00 crore, with a paid-up capital of ₹2.60 crore. As of April 8, 2024, the company employed 56 professionals, including skilled pharmacists and quality control specialists. The leadership team comprises Directors Santosh Waman Mutkule, Ramesh Narandas Rughani, and Sunanda Vaman Mutkule.

What Does Sanpras Healthcare Private Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Lactulose$1.2M 2Ambroxol

Product Portfolio — Top 4 by Export Value

Sanpras Healthcare Private Limited exports 4 pharmaceutical products across 3 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Lactulose	Gastrointestinal	$1.2M	47	8.0%	4
2	Ambroxol	Respiratory & OTC	$551.0K	39	3.7%	6
3	Bromhexine	Respiratory & OTC	$359.7K	36	2.2%	8
4	Melatonin	Nutritional Supplements	$149.7K	3	1.6%	12

Sanpras Healthcare Private Limited exports 4 pharmaceutical products across 3 therapeutic categories with a total export value of $2.3M. The top category is Gastrointestinal (53.1% of portfolio), followed by Respiratory & OTC (40.3%), indicating a concentrated portfolio with the top 5 products accounting for 100.0% of total export value.

Sanpras Healthcare Private Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Sanpras Healthcare operates a dedicated oral liquid manufacturing plant located in Musalgaon, Sinnar, Maharashtra. This facility is equipped to produce a wide range of oral liquid formulations, catering to both pediatric and adult patients. The plant adheres to Good Manufacturing Practices (GMP) guidelines, ensuring the production of high-quality and safe pharmaceutical products.

3Key Leadership

The company's leadership includes Directors Santosh Waman Mutkule, Ramesh Narandas Rughani, and Sunanda Vaman Mutkule. These individuals bring extensive experience in the pharmaceutical industry, contributing to the company's strategic direction and operational success.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Sanpras Healthcare Private Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Sanpras Healthcare's export portfolio, valued at $2.3 million USD across 125 shipments, includes products such as Lactulose, Ambroxol, Bromhexine, and Melatonin. The company's focus on finished pharmaceutical formulations positions it to meet the stringent regulatory requirements of markets like the United States, European Union, United Kingdom, Australia, and Japan. While specific regulatory approvals are not detailed, the company's adherence to GMP standards suggests a commitment to meeting international quality benchmarks.

2Emerging Markets

Sanpras Healthcare's export activities indicate a presence in emerging markets, including regions in Africa, Latin America, and Southeast Asia. The company's adherence to WHO GMP guidelines enhances its potential for obtaining WHO prequalification, facilitating access to these markets. However, specific details regarding market penetration and prequalification status are not provided.

3Geographic Strategy

Sanpras Healthcare's export strategy demonstrates a diversified approach, with products spanning therapeutic categories such as Gastrointestinal (53.1%), Respiratory & OTC (40.3%), and Nutritional Supplements (6.6%). This diversification mitigates concentration risk and aligns with the company's strategic direction to serve a broad patient base.

Sanpras Healthcare Private Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Specific details regarding Sanpras Healthcare's FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history are not publicly available. The company's adherence to GMP standards suggests a commitment to meeting international quality benchmarks, which is essential for FDA approvals.

2WHO & EU GMP

Sanpras Healthcare's manufacturing facility adheres to WHO GMP guidelines, ensuring the production of high-quality pharmaceutical products. While specific certifications such as WHO prequalification or EU GMP certificates are not detailed, the company's commitment to quality suggests potential for obtaining these certifications.

3CDSCO & Indian Regulatory

Sanpras Healthcare holds manufacturing licenses from the Central Drugs Standard Control Organisation (CDSCO), ensuring compliance with Indian regulatory standards. The company's adherence to GMP guidelines further supports its compliance with Indian regulatory requirements.

Sanpras Healthcare Private Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Sanpras Healthcare operates in a competitive landscape with companies such as Zuventus HealthCare, Windlas Biotech, and Shenzhen Tsumura Medicine. While specific market share comparisons are not available, Sanpras Healthcare's diversified product portfolio and adherence to quality standards position it favorably in the market.

2Key Differentiators

Sanpras Healthcare's focus on high-quality oral liquid formulations, adherence to GMP guidelines, and commitment to customer satisfaction distinguish it in the pharmaceutical industry. The company's dedicated manufacturing facility and experienced leadership team further enhance its competitive advantages.

3Strategic Position

Sanpras Healthcare's strategic direction emphasizes the production of high-quality, affordable pharmaceutical products across various therapeutic segments. The company's adherence to GMP standards and focus on customer satisfaction align with its mission to serve the healthcare sector both nationally and internationally.

Buyer Due Diligence Brief — Evaluating Sanpras Healthcare Private Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Sanpras Healthcare's export volume and consistency, along with its adherence to GMP standards, indicate a reliable track record as a pharmaceutical supplier. The company's commitment to quality and customer satisfaction further enhance its reliability indicators.

2Certifications to Verify

Importers should verify certifications such as WHO GMP, EU GMP, and ISO standards to ensure product quality and compliance. Verification can be conducted through official regulatory bodies or by requesting certification documents directly from the supplier.

3Due Diligence Checklist

Verify manufacturing licenses and certifications.
Assess product quality through sample testing.

Frequently Asked Questions — Sanpras Healthcare Private Limited

How many pharmaceutical products does Sanpras Healthcare Private Limited export from India?

Sanpras Healthcare Private Limited exports 4 pharmaceutical products across 3 therapeutic categories. The top exports are Lactulose ($1.2M), Ambroxol ($551.0K), Bromhexine ($359.7K), Melatonin ($149.7K). Total export value is $2.3M.

What is Sanpras Healthcare Private Limited's total pharmaceutical export value?

Sanpras Healthcare Private Limited's total pharmaceutical export value is $2.3M, based on 125 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does Sanpras Healthcare Private Limited cover?

Sanpras Healthcare Private Limited exports across 3 therapeutic categories. The largest are Gastrointestinal (53.1%, 1 products), Respiratory & OTC (40.3%, 2 products), Nutritional Supplements (6.6%, 1 products).

Get Full Sanpras Healthcare Private Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. Profile aggregates 2 company name variants from customs records. For current shipment-level data, contact TransData Nexus.